Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation and Depletion (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Depreciation and Depletion for 11 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion rose 20.0% to $600000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 100.0% increase, with the full-year FY2025 number at $2.4 million, up 100.0% from a year prior.
  • Depreciation and Depletion was $600000.0 for Q4 2025 at Cartesian Therapeutics, roughly flat from $600000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $600000.0 in Q1 2025 to a low of $100000.0 in Q1 2021.
  • A 5-year average of $280000.0 and a median of $200000.0 in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: crashed 50.0% in 2021, then skyrocketed 200.0% in 2024.
  • Cartesian Therapeutics' Depreciation and Depletion stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then soared by 150.0% to $500000.0 in 2024, then rose by 20.0% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Depreciation and Depletion are $600000.0 (Q4 2025), $600000.0 (Q3 2025), and $600000.0 (Q2 2025).